In this episode we delve into the evolving landscape of multiple sclerosis treatment, focusing on generics and biosimilars. It features a conversation with pharmacist Lucy Wessels, highlighting the safety, effectiveness, and cost benefits of generics and biosimilars in managing MS. The discussion emphasizes the importance of patient education, collaborative decision-making with healthcare providers, and dispelling misconceptions like the 'nocebo' effect around these treatment option. 00:00 Welcome and Introduction to the Episode01:06 Understanding Generics and Biosimilars in MS Treatment03:42 Diving Deeper: The Difference Between Generics and Biosimilars11:58 Addressing Concerns: Side Effects and Tolerability14:34 Enhancing Patient Understanding and Acceptance20:22 The Nocebo Effect and Its Impact on Treatment Perception24:34 Future of MS Treatment: Embracing Generics and Biosimilars31:52 Concluding Thoughts and Key TakeawaysBecome a supporter of this podcast: https://www.spreaker.com/podcast/beewellwithms-podcast-by-dr-agne-straukiene--5762905/support.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related